These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 19850869

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Xu X, Liu Y, Gong Q, Ma L, Wei W, Zhao L, Luo Z.
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):209-221. PubMed ID: 38609654
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
    Hong Z, Cao X, Li N, Zhang Y, Lan L, Zhou Y, Pan X, Shen L, Yin Z, Luo L.
    Br J Pharmacol; 2014 Jun 31; 171(11):2842-53. PubMed ID: 24471765
    [Abstract] [Full Text] [Related]

  • 33. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D.
    PLoS One; 2013 Jun 31; 8(7):e68966. PubMed ID: 23935914
    [Abstract] [Full Text] [Related]

  • 34. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.
    J Clin Invest; 2006 Oct 31; 116(10):2695-706. PubMed ID: 16906227
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
    Xu J, Zeng LF, Shen W, Turchi JJ, Zhang ZY.
    Biochem Biophys Res Commun; 2013 Oct 04; 439(4):586-90. PubMed ID: 24041688
    [Abstract] [Full Text] [Related]

  • 37. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
    Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.
    Cancer Discov; 2012 Oct 04; 2(10):934-47. PubMed ID: 22961667
    [Abstract] [Full Text] [Related]

  • 38. Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
    Han SY, Ding HR, Zhao W, Teng F, Li PP.
    BMC Complement Altern Med; 2014 May 22; 14():165. PubMed ID: 24884778
    [Abstract] [Full Text] [Related]

  • 39. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
    Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.
    Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074
    [Abstract] [Full Text] [Related]

  • 40. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.
    Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC.
    Bioinformatics; 2014 Sep 01; 30(17):2393-8. PubMed ID: 24812339
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.